Latest FDA Stories

Ultherapy is a non-surgical ultrasound treatment FDA-approved to lift skin on the neck, on the brow and under the chin. NYC,NY (PRWEB) May 25, 2013 Dr. Leslie Gerstman announced today that Ultherapy-- the only non-invasive procedure FDA-approved to lift skin on the neck, on the brow and under the chin -- is now available at her practice, Medical Aesthetics. Ultherapy is a non-surgical procedure for the face and neck that stimulates the body’s own natural healing process to lift the skin...

New information from d’Oliveira & Associates helps you evaluate the risks of taking antidepressants during pregnancy. (PRWEB) May 23, 2013 During pregnancy both the health of the mother and the growing fetus are affected by medical treatments, especially medication. In July 2006, a study published by the New England Journal of Medicine prompted the FDA to warn about a potential link between certain antidepressant drugs and serious birth defects such as persistent pulmonary...

Dr. Damon Huffman now offers laser periodontal disease treatment to Humble, TX patients suffering from gum disease. Utilizing the FDA-cleared Laser Assisted New Attachment Procedure, Dr. Huffman is able to remove diseased tissue without cutting healthy gum tissue. Humble, TX (PRWEB) May 23, 2013 Dr. Damon Huffman of Huffman Family Dentistry is now able to offer patients who suffer from gum disease a revolutionary new treatment method with the Laser Assisted New Attachment Procedure....

Dermasis psoriasis treatment cream has been released online for men and women courtesy of Dermasis.com. This new FDA registered company is now offering its natural solution to help ease the itching, burning and appearance of Psoriasis infected skin. Los Angeles,Ca (PRWEB) May 24, 2013 Psoriasis treatment cream has been released online for men and women courtesy of Dermasis.com. This new FDA registered company is now offering its natural solution to help ease the itching, burning and...

Across-the-board cuts threaten innovation and patient access to new technologies (LA JOLLA, Calif.) (PRWEB) May 24, 2013 CHI-California Healthcare Institute today submitted a letter to House Appropriators and the California congressional delegation, joined by over 40 biomedical companies, urging them to restore sequestered industry user fees paid to the U.S. Food and Drug Administration in 2013, and to ensure that future across-the-board cuts will not include user fees paid to FDA, as...

IRVINE, Calif., May 24, 2013 /PRNewswire/ -- Andrew Technologies applauds the courage of actress Angelina Jolie and reporter Zoraida Sambolin of CNN to go public about their own personal experiences with breast cancer. This terrible disease has devastated the lives of many women and some men; and left many women with concerns about their perceived diminished femininity. Since HydraSolve® Lipoplasty System from Andrew Technologies is now the first FDA-cleared liposuction device for...

CASTLE ROCK, Colo., May 23, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test, APPY1, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and related warrants to purchase 3,500,000 shares of its common stock at an exercise price of $1.36 per share at a combined public offering price of $1.25 per...

GURGAON, India, May 23, 2013 /PRNewswire/ -- On 22 May 2013, Daiichi Sankyo released a press statement where, among other things, it was stated that it "believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the US DOJ and FDA investigations". The phrase is an obvious reference to the members and companies of the Singh family who were shareholders of Ranbaxy. Daiichi Sankyo's allegations of concealment...

Public Advisory Panel Accepts FDA's Class II Re-Classification Suggestion FREDERICK, Md., May 23, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very effective, safe consumer medical devices, comments on the FDA panel meeting for non-thermal shortwave diathermy: The FDA's Public Advisory Panel Reclassification - Pulsed Shortwave Therapy Meeting was held on May 21, 2013 in Gaithersburg, MD, USA. The focus of the meeting was very narrow, in that the...

-- Clinical Trial in Patients with Huntington's Disease Slated to Begin Next Quarter -- SEATTLE, May 23, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect...